Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Rogier, Rebecca ^a   Evans Marin, Heather ^b   Manasson, Julia ^b   Van Der Kraan, Peter M ^a   Walgreen, Birgitte ^a   Helsen, Monique M ^a   Van Den Bersselaar, Liduine A ^a   Van De Loo, Fons A ^a   Van Lent, Peter L ^a   Abramson, Steven B ^b   Van Den Berg, Wim B ^a   Koenders, Marije I ^a   Scher, Jose U ^b   Abdollahi Roodsaz, Shahla ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S; SERUM AMYLOID A;

ANIMAL; BACTEROIDETES; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; FIRMICUTES; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; MOUSE; PATHOLOGY; PROTEOBACTERIA; TH1 CELL; TH17 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BACTEROIDETES; DISEASE MODELS, ANIMAL; FIRMICUTES; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; MICE; PROTEOBACTERIA; RNA, RIBOSOMAL, 16S; SERUM AMYLOID A PROTEIN; TH1 CELLS; TH17 CELLS;

EID: 85034437574     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-15802-x     Document Type: Article

References (80)

1. Abdollahi-Roodsaz, S., Abramson, S. B. & Scher, J. U. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nature reviews. Rheumatology 12, 446-455 (2016).
2. Scher, J. U., Littman, D. R. & Abramson, S. B. Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis & rheumatology (Hoboken, N.J.) 68, 35-45 (2016).
3. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205-2219 (2011).
4. Schett, G., Coates, L. C., Ash, Z. R., Finzel, S. & Conaghan, P. G. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis research & therapy 13(Suppl 1), S4 (2011).
5. Scher, J. U. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis & rheumatology (Hoboken, N.J.) 67, 128-139 (2015).
6. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2, e01202 (2013).
7. Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 21, 895-905 (2015).
8. Maeda, Y. et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis & rheumatology (2016).
9. Chen, J. et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome medicine 8, 43 (2016).
10. Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75-84 (2016).
11. Kamada, N. & Nunez, G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 146, 1477-1488 (2014).
12. Lubberts, E. The IL-23-IL-17 axis in inflammatory arthritis. Nature reviews. Rheumatology 11, 415-429 (2015).
13. van den Berg, W. B. & McInnes, I. B. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 43, 158-170 (2013).
14. Avci, A. B., Feist, E. & Burmester, G. R. Targeting GM-CSF in rheumatoid arthritis. Clinical and experimental rheumatology 34, 39-44 (2016).
15. Wicks, I. P. & Roberts, A. W. Targeting GM-CSF in inflammatory diseases. Nature reviews. Rheumatology 12, 37-48 (2016).
16. Tesmer, L. A., Lundy, S. K., Sarkar, S. & Fox, D. A. Th17 cells in human disease. Immunological reviews 223, 87-113 (2008).
17. Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. The New England journal of medicine 370, 2295-2306 (2014).
18. Mease, P. J. et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 373, 1329-1339 (2015).
19. Genovese, M. C. et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis & rheumatology (Hoboken, N.J.) 66, 1693-1704 (2014).
20. Genovese, M. C. et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dosefinding, double-blind, randomized, placebo-controlled study. The Journal of rheumatology 41, 414-421 (2014).
21. Burmester, G. R. et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology (Oxford, England) 55, 49-55 (2016).
22. Koenders, M. I. et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167, 141-149 (2005).
23. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203, 2673-2682 (2006).
24. Kotake, S. et al. IL?17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103, 1345-1352 (1999).
25. Hot, A. & Miossec, P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Annals of the rheumatic diseases 70, 727-732 (2011).
26. Rehaume, L. M. et al. ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. Arthritis & rheumatology (Hoboken, N.J.) 66, 2780-2792 (2014).
27. Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 118, 205-216 (2008).
28. Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815-827 (2010).
29. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485-498 (2009).
30. Sano, T. et al. An IL-23R/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses. Cell 163, 381-393 (2015).
31. Ochoa-Reparaz, J. et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md.: 1950) 183, 6041-6050 (2009).
32. Rosser, E. C. et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med 20, 1334-1339 (2014).
33. Marietta, E. V. et al. Human Gut-Derived Prevotella histicola Suppresses Inflammatory Arthritis in Humanized Mice. Arthritis & rheumatology (2016).
34. Hill, D. A. et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol 3, 148-158 (2010).
35. Isaac, S. et al. Short-and long-term effects of oral vancomycin on the human intestinal microbiota. The Journal of antimicrobial chemotherapy 72, 128-136 (2017).
36. Lee, Y. K., Menezes, J. S., Umesaki, Y. & Mazmanian, S. K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 108(Suppl 1), 4615-4622 (2011).
37. Barman, M. et al. Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract. Infect Immun 76, 907-915 (2008).
38. Korganow, A. S. et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10, 451-461 (1999).
39. Kyburz, D. & Corr, M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol 25, 79-90 (2003).
40. Maeda, Y. et al. Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis & rheumatology (Hoboken, N.J.) 68, 2646-2661 (2016).
41. van de Stadt, L. A. et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis and rheumatism 63, 3226-3233 (2011).
42. Deane, K. D. et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis and rheumatism 62, 3161-3172 (2010).
43. van der Woude, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Annals of the rheumatic diseases 69, 1554-1561 (2010).
44. Liu, X. et al. Role of the Gut Microbiome in Modulating Arthritis Progression in Mice. Scientific reports 6, 30594 (2016).
45. Ben-Amram, H. et al. Tuftsin-Phosphorylcholine Maintains Normal Gut Microbiota in Collagen Induced Arthritic Mice. Frontiers in microbiology 8, 1222 (2017).
46. Rogier, R. et al. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17-and TLR4-dependent arthritis. Microbiome 5, 63 (2017).
47. Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. The ISME journal 5, 82-91 (2011).
48. Gaboriau-Routhiau, V. et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31, 677-689 (2009).
49. Hannonen, P., Mottonen, T., Hakola, M. & Oka, M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis and rheumatism 36, 1501-1509 (1993).
50. Stone, M., Fortin, P. R., Pacheco-Tena, C. & Inman, R. D. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. The Journal of rheumatology 30, 2112-2122 (2003).
51. Morton, A. M. et al. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl Acad Sci USA 111, 6696-6701 (2014).
52. Hwang, Y. G. et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis research & therapy 18, 108 (2016).
53. Gabay, C. et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Annals of the rheumatic diseases 75, 1806-1812 (2016).
54. Migita, K. et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clinical and experimental immunology 175, 208-214 (2014).
55. Shen, C. et al. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis. Molecular medicine reports 11, 1528-1534 (2015).
56. Targonska-Stepniak, B. & Majdan, M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators of inflammation 2014, 793628 (2014).
57. Hong, C. et al. An involvement of SR-B1 mediated p38 MAPK signaling pathway in serum amyloid A-induced angiogenesis in rheumatoid arthritis. Molecular immunology 66, 340-345 (2015).
58. Connolly, M. et al. Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. Annals of the rheumatic diseases 75, 1392-1398 (2016).
59. da Rocha, L. F. Jr. et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. The Journal of rheumatology 39, 1320-1325 (2012).
60. Ikeuchi, H. et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis and rheumatism 52, 1037-1046 (2005).
61. Leipe, J. et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Annals of the rheumatic diseases 70, 1453-1457 (2011).
62. Benham, H. et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis research & therapy 15, R136 (2013).
63. Block, K. E., Zheng, Z., Dent, A. L., Kee, B. L. & Huang, H. Gut Microbiota Regulates K/BxN Autoimmune Arthritis through Follicular Helper T but Not Th17 Cells. Journal of immunology (Baltimore, Md.: 1950) 196, 1550-1557 (2016).
64. Jacobs, J. P., Wu, H. J., Benoist, C. & Mathis, D. IL-17-producing T cells can augment autoantibody-induced arthritis. Proc Natl Acad Sci USA 106, 21789-21794 (2009).
65. Shi, G. et al. Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. Journal of immunology (Baltimore, Md.: 1950) 181, 7205-7213 (2008).
66. Basdeo, S. A. et al. Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells. Journal of immunology (Baltimore, Md.: 1950) 198, 2249-2259 (2017).
67. Leipe, J. et al. Role of Th17 cells in human autoimmune arthritis. Arthritis and rheumatism 62, 2876-2885 (2010).
68. Colin, E. M. et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis and rheumatism 62, 132-142 (2010).
69. van Hamburg, J. P. et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis and rheumatism 63, 73-83 (2011).
70. van Hamburg, J. P. et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Annals of the rheumatic diseases 72, 1700-1707 (2013).
71. Yamada, H. et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Annals of the rheumatic diseases 67, 1299-1304 (2008).
72. Miao, J. et al. Frequencies of circulating IL-17-producing CD4 + CD161 + T cells and CD4 + CD161 + T cells correlate with disease activity in rheumatoid arthritis. Modern rheumatology 24, 265-570 (2014).
73. Chalan, P. et al. Circulating CD4 + CD161 + T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritis. PloS one 8, e79370 (2013).
74. Jandus, C. et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis and rheumatism 58, 2307-2317 (2008).
75. Raychaudhuri, S. K., Saxena, A. & Raychaudhuri, S. P. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clinical rheumatology 34, 1019-1023 (2015).
76. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis and rheumatism 39, 797-809 (1996).
77. Scher, J. U. et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 4, 60 (2016).
78. McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. The ISME journal 6, 610-618 (2012).
79. Abdollahi-Roodsaz, S. et al. Toll-like receptor 2 controls acute immune complex-driven arthritis in mice by regulating the inhibitory Fcgamma receptor IIB. Arthritis and rheumatism 65, 2583-2593 (2013).
80. Abdollahi-Roodsaz, S. et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis and rheumatism 56, 2957-2967 (2007).